IL285699A - Amyloid peptide variants - Google Patents

Amyloid peptide variants

Info

Publication number
IL285699A
IL285699A IL285699A IL28569921A IL285699A IL 285699 A IL285699 A IL 285699A IL 285699 A IL285699 A IL 285699A IL 28569921 A IL28569921 A IL 28569921A IL 285699 A IL285699 A IL 285699A
Authority
IL
Israel
Prior art keywords
amyloid peptide
peptide variants
variants
amyloid
peptide
Prior art date
Application number
IL285699A
Other languages
English (en)
Hebrew (he)
Original Assignee
Loyola Marymount Univ
Mount Saint Marys Univ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Loyola Marymount Univ, Mount Saint Marys Univ filed Critical Loyola Marymount Univ
Publication of IL285699A publication Critical patent/IL285699A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IL285699A 2019-02-22 2021-08-18 Amyloid peptide variants IL285699A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962809167P 2019-02-22 2019-02-22
PCT/US2020/019557 WO2020172686A1 (en) 2019-02-22 2020-02-24 Amyloid peptide variants

Publications (1)

Publication Number Publication Date
IL285699A true IL285699A (en) 2021-10-31

Family

ID=72145021

Family Applications (1)

Application Number Title Priority Date Filing Date
IL285699A IL285699A (en) 2019-02-22 2021-08-18 Amyloid peptide variants

Country Status (6)

Country Link
US (2) US12522635B2 (https=)
EP (1) EP3927725A4 (https=)
JP (2) JP7505713B2 (https=)
CN (2) CN118955675A (https=)
IL (1) IL285699A (https=)
WO (1) WO2020172686A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021233942A1 (en) * 2020-05-19 2021-11-25 Empa Eidgenössische Materialprüfungs- Und Forschungsanstalt Detection and imaging of amyloid aggregates in blood

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE454299B (sv) * 1986-10-08 1988-04-18 Westermark P Sats innehallande polypeptid som finns i pankreasoamyloid och/eller antikroppar riktade mot polypeptiden
HU222249B1 (hu) * 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
US5814600A (en) * 1991-05-24 1998-09-29 Amylin Pharmaceuticals Inc. Method and composition for treatment of insulin requiring mammals
US7060670B1 (en) * 1999-05-05 2006-06-13 Neurochem (International) Limited Stereoselective antifibrillogenic peptides and peptidomimetics thereof
ATE514707T1 (de) * 2002-04-19 2011-07-15 Univ Toronto Immunologisches verfahren und zusammensetzungen für die behandlung der krankheit von alzheimer
JP2007527365A (ja) * 2003-03-18 2007-09-27 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ アミリン凝集阻害剤およびその使用
DE102004051014A1 (de) * 2004-10-20 2006-04-27 Rwth Aachen Chemisch modifizierte Peptidanaloga
GB0501348D0 (en) * 2005-01-24 2005-03-02 Zyentia Ltd Compositions and methods
AU2006341375B2 (en) * 2006-03-31 2013-03-21 Amylin Pharmaceuticals, Llc Amylin and amylin agonists for treating psychiatric diseases and disorders
EP2036923A1 (en) * 2007-09-11 2009-03-18 Novo Nordisk A/S Improved derivates of amylin
CA2812951A1 (en) 2010-09-28 2012-04-19 Amylin Pharmaceuticals, Llc Engineered polypeptides having enhanced duration of action
US20130022620A1 (en) * 2011-06-09 2013-01-24 Ann Marie Schmidt Assays and methods pertaining to pre-amyloid intermediates
JP6121992B2 (ja) * 2011-06-10 2017-04-26 ノヴォ ノルディスク アー／エス ポリペプチド
US9475866B2 (en) * 2012-09-12 2016-10-25 Neurimmune Holding Ag Human islet amyloid polypeptide (hIAPP) specific antibodies and uses thereof
WO2015062803A1 (en) * 2013-10-29 2015-05-07 Kapurniotu Aphrodite Modified segments of islet amyloid polypeptide
CN108070075A (zh) * 2016-11-09 2018-05-25 可口可乐公司 生物基meg和聚酯纤维组合物以及制造它们的方法
WO2018144671A1 (en) * 2017-02-01 2018-08-09 The Research Foundation For The State University Of New York Mutant islet amyloid polypeptides with improved solubility and methods for using the same
WO2019241628A1 (en) * 2018-06-15 2019-12-19 Proclara Biosciences, Inc. General amyloid interaction motif (gaim)

Also Published As

Publication number Publication date
JP2024125307A (ja) 2024-09-18
JP2022521266A (ja) 2022-04-06
US20220119468A1 (en) 2022-04-21
EP3927725A1 (en) 2021-12-29
US12522635B2 (en) 2026-01-13
WO2020172686A1 (en) 2020-08-27
US20260109744A1 (en) 2026-04-23
WO2020172686A9 (en) 2020-11-12
CN113614101B (zh) 2024-07-16
JP7825238B2 (ja) 2026-03-06
JP7505713B2 (ja) 2024-06-25
CN118955675A (zh) 2024-11-15
CN113614101A (zh) 2021-11-05
EP3927725A4 (en) 2023-06-14

Similar Documents

Publication Publication Date Title
IL269003A (en) Anti-n3pglu amyloid beta peptide antibodies and uses thereof
UA42395S (uk) Футляр
EP3802852A4 (en) MANIPULATED CYCLIC PEPTIDES
EP4079231A4 (en) Sheath
EP4069225A4 (en) COMBINATIONS
EP3930851A4 (en) COMBINATION THERAPIES
EP3919491C0 (en) AKT INHIBITOR
EP4028409A4 (en) NEW PEPTIDES
EP3742771C0 (en) M2M SM-SR TO SM-DP NOTIFICATION
DK3840767T3 (da) Peptider
DK3737402T5 (da) Modificeret protein
EP3897128A4 (en) ANTIMICROBIAL PEPTIDES
EP4069241A4 (en) COMBINATIONS
EP4069240A4 (en) ASSOCIATIONS
EP4013440A4 (en) THERAPEUTIC PEPTIDES
EP3912517C0 (en) FRAME
PL3755363T3 (pl) Warianty plantarycyny nc8alfabeta
EP3957391C0 (en) AGITATOR
IL289460A (en) Modified bcl9 mimetic peptides
EP3962498A4 (en) Combination therapies
IL311773A (en) Peptide
DK3738452T3 (da) Fordamper
EP3870698A4 (en) ANTIPATHOGENIC POLYPEPTIDES
EP3682831C0 (en) CRYOGENIC APPLICATOR
IL285699A (en) Amyloid peptide variants